Custom Pharma Services
Ripal Sheth has over 25 years of experience in the pharmaceutical industry, currently serving as a Senior Analytical Development Analyst at Custom Pharma Services since August 2008. Prior roles at Custom Pharma Services include Analytical Development Analyst, Quality Control Analyst, and Quality Control Technician. Prior to this, Ripal served as a Senior QC Officer at Sterling BioTech Ltd from January 1999 to January 2007 and worked as a Chemist at Esskay Pharmaceuticals Ltd from August 1997 to December 1999. Ripal holds a Master's degree in Organic Chemistry and a Bachelor of Science (B.Sc.) in Chemistry, both obtained from Gujarat University, with completion dates in 1999 and 1997, respectively.
This person is not in the org chart
This person is not in any teams
Custom Pharma Services
1 followers
Custom Pharma Services is located in Brighton, UK since 1979 and is a full-service contract development and manufacturing organisation (CDMO) providing services tailored to your needs, no matter how niche or complex. Custom covers the full spectrum of activities from development through commercial manufacturing for both clinical and commercial use. Specialising in Oral Solid Dosage forms with the ability to handle highly potent drugs and poorly bioavailable compounds Custom really is your one stop resource. With direct access to highly skilled experts offering a partnership approach Custom Pharma Services truly has a molecule first mentality, managing all projects with the end in mind. Custom Can! • Custom Pharma is a CDMO offering clinical and commercial manufacturing of tablets, capsules, powders (oral-solid-dose) for human use. • Services comprise pre-formulation and formulation development, analytical development, stability testing, clinical trial material manufacturing • Commercial Production • Pre-clinical formulation development and solubilisation • Material characterisation • Drug in capsule approach to accelerate early clinical studies • Specialists in low dosage (sub-mg) formulations • Contained manufacturing for highly potent APIs • Orphan drug development • Formulation development of poorly soluble drugs, including spray drying capabilities